Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model

Drug-induced liver injury induced by already approved substances is a major threat to human patients, potentially resulting in drug withdrawal and substantial loss of financial resources in the pharmaceutical industry. Trovafloxacin, a broad-spectrum fluoroquinolone, was found to have unexpected sid...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2023-08, Vol.13 (1), p.13338-13338, Article 13338
Main Authors: Kaden, Tim, Graf, Katja, Rennert, Knut, Li, Ruoya, Mosig, Alexander S., Raasch, Martin
Format: Article
Language:English
Subjects:
631/154
631/154/1435
631/154/1438
631/154/570
631/61
631/61/2035
631/80
Animal research
Antibiotics
Cell differentiation
Cytokines
Cytotoxicity
Endothelial cells
Glutathione
Hepatocytes
Hepatotoxicity
Humanities and Social Sciences
Immune response
Inflammation
Levofloxacin
Liver
Macrophages
Monocytes
multidisciplinary
Pharmaceutical industry
Science
Science (multidisciplinary)
Side effects
Toxicity
Trovafloxacin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug-induced liver injury induced by already approved substances is a major threat to human patients, potentially resulting in drug withdrawal and substantial loss of financial resources in the pharmaceutical industry. Trovafloxacin, a broad-spectrum fluoroquinolone, was found to have unexpected side effects of severe hepatotoxicity, which was not detected by preclinical testing. To address the limitations of current drug testing strategies mainly involving 2D cell cultures and animal testing, a three-dimensional microphysiological model of the human liver containing expandable human liver sinusoidal endothelial cells, monocyte-derived macrophages and differentiated HepaRG cells was utilized to investigate the toxicity of trovafloxacin and compared it to the structurally-related non-toxic drug levofloxacin. In the model, trovafloxacin elicited vascular and hepatocellular toxicity associated with pro-inflammatory cytokine release already at clinically relevant concentrations, whereas levofloxacin did not provoke tissue injury. Similar to in vivo, cytokine secretion was dependent on a multicellular immune response, highlighting the potential of the complex microphysiological liver model for reliably detecting drug-related cytotoxicity in preclinical testing. Moreover, hepatic glutathione depletion and mitochondrial ROS formation were elucidated as intrinsic toxicity mechanisms contributing to trovafloxacin toxicity.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-40004-z